<div id="readability-page-1">PharmaCyte Biotech Inc. (NASDAQ:PMCB) shares skyrocketed 67.8% on Tuesday after the company announced it had completed the successful monetization of its stake in Femasys Inc. (NASDAQ:FEMY), significantly bolstering its liquidity. The sale is projected to lift PharmaCyte’s combined cash and marketable securities to roughly $20 million, up from $13.3 million reported as of July 31, […]</div>

PMCB

FEMY

<p>PharmaCyte Biotech Inc.（纳斯达克代码：PMCB）股价上涨 67.8%，因成功变现其在 Femasys Inc.（纳斯达克代码：FEMY）中的股份，增强了流动性。此次出售使 PharmaCyte 的现金和可交易证券增加至约 2000 万美元，较之前的 1330 万美元有所上升</p>

PharmaCyte Biotech 股票在成功从 Femasys 投资中获利退出后大幅上涨